Home  /  Resource Library  /  Obinutuzumab (G) plus fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of CLL patients: the phase 1b GALTON trial

Obinutuzumab (G) plus fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of CLL patients: the phase 1b GALTON trial

Key points – In this Phase 1b study, obinutuzumab plus FC or B had an acceptable safety profile, with infusion reactions the most common adverse event. Obinutuzumab plus FC or B showed promising clinical activity in the initial treatment of CLL, with no relapses to date.